M&A

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Transom Capital Group appoints Luke Dauch, a decade-long J.P. Morgan banker, to bolster its deal origination in a competitive middle-market landscape.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The oil producer's new BBB- ratings signal deep financial strength, unlocking lower borrowing costs, enhanced strategic options, and greater shareholder value.

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

Kestrel Group reports soaring fee income from its core business, but a quarterly loss reveals the deep financial drag from its complex merger with Maiden Holdings.

The European FinTech giant plans a new €70M note issue and a tender offer to refinance debt, signaling a major push for financial flexibility and expansion.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

Denver M&A firm SDR Ventures promotes veteran advisor Scott Mitchell, doubling down on its client-centric strategy for entrepreneurs in a competitive market.

Palmer Square Capital BDC reports a drop in 2025 income and asset value but highlights rock-solid credit quality and an optimistic outlook for 2026.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

EPIC Insurance creates a new leadership role for Miranda Rodriguez, a strategic move to scale its real estate practice and challenge market leaders.

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.

Leaving the volatile crypto world behind, Cipher Digital is raising billions to build massive data centers for tech giants like AWS and Google.

Despite a stock dip, Select Water Solutions' major offering signals a strategic push for growth in water recycling, acquisitions, and infrastructure.

Ditching passive holding, Lite Strategy generated $600k from Litecoin options to fund buybacks. Is this the new playbook for corporate crypto finance?

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.